MiR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13

Nature Communications

Volumn 5, Issue , 2014, Pages

  Zhang, Peijing ^a   Wang, Li ^a   Rodriguez Aguayo, Cristian ^a   Yuan, Yuan ^a   Debeb, Bisrat G ^a   Chen, Dahu ^a   Sun, Yutong ^b   You, M James ^a   Liu, Yongqing ^c   Dean, Douglas C ^c   Woodward, Wendy A ^a   Liang, Han ^a   Yang, Xianbin ^b   Lopez Berestein, Gabriel ^a   Sood, Anil K ^a   Hu, Ye ^d   Ang, K Kian ^a   Chen, Junjie ^a,e   Ma, Li ^a,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Experimental Therapeutics University of Texas MD Anderson Cancer Center ^*  (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2AX; LIPOSOME; MICRORNA 205; MIRAVIRSEN; NANOPARTICLE; RADIOSENSITIZING AGENT; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ZEB1; UBIQUITIN CONJUGATING ENZYME 13; ATM PROTEIN; ATM PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MICRORNA; MIRN25 MICRORNA, HUMAN; TRANSCRIPTION FACTOR; UBE2N PROTEIN, HUMAN; UBIQUITIN CONJUGATING ENZYME; ZEB1 PROTEIN, HUMAN;

CHEMICAL BINDING; CYTOLOGY; DRUG RESISTANCE; INHIBITION; NANOTECHNOLOGY; SUBPOPULATION; TUMOR;

3' UNTRANSLATED REGION; A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL TRANSDIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENETIC TRANSFECTION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; U2OS CELL LINE; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; DNA REPAIR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; NEOPLASMS; RADIATION TOLERANCE; TRANSCRIPTION FACTORS; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84923383604     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6671     Document Type: Article

References (65)

1. Jameel, J. K., Rao, V. S., Cawkwell, L. & Drew, P. J. Radioresistance in carcinoma of the breast. Breast 13, 452-460 (2004).
2. Horsman, M. R. et al. Tumor radiosensitizers-current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int. J. Radiat. Oncol. Biol. Phys. 64, 551-561 (2006).
3. Calin, G. A. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002).
4. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005).
5. Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007).
6. Iorio, M. V. & Croce, C. M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27, 5848-5856 (2009).
7. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
8. Bader, A. G., Brown, D., Stoudemire, J. & Lammers, P. Developing therapeutic microRNAs for cancer. Gene Therapy 18, 1121-1126 (2011).
9. Kasinski, A. L. & Slack, F. J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11, 849-864 (2011).
10. Ling, H., Fabbri, M. & Calin, G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847-865 (2013).
11. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. New Engl. J. Med. 368, 1685-1694 (2013).
12. Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341-347 (2010).
13. Liu, C. et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17, 211-215 (2011).
14. Ell, B. et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24, 542-556 (2013).
15. Taira, N. et al. Induction of amphiregulin by p53 promotes apoptosis via control of microRNA biogenesis in response to DNA damage. Proc. Natl Acad. Sci. USA 111, 717-722 (2014).
16. Sun, C. et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J. Natl Cancer Inst. 105, 1750-1758 (2013).
17. Zhou, Y. et al. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol. Oncol. 8, 83-92 (2014).
18. Martin, N. T. et al. ATM-dependent MiR-335 targets CtIP and modulates the DNA damage response. PLoS Genet. 9, e1003505 (2013).
19. Chowdhury, D., Choi, Y. E. & Brault, M. E. Charity begins at home: non-coding RNA functions in DNA repair. Nat. Rev. Mol. Cell Biol. 14, 181-189 (2013).
20. Metheetrairut, C. & Slack, F. J. MicroRNAs in the ionizing radiation response and in radiotherapy. Curr. Opin. Genet. Dev. 23, 12-19 (2013).
21. Banath, J. P., Macphail, S. H. & Olive, P. L. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res. 64, 7144-7149 (2004).
22. Olive, P. L. & Banath, J. P. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 58, 331-335 (2004).
23. Taneja, N. et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J. Biol. Chem. 279, 2273-2280 (2004).
24. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
25. Baumann, M., Krause, M. & Hill, R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8, 545-554 (2008).
26. Phillips, T. M., McBride, W. H. & Pajonk, F. The response of CD24(-/low)/CD44 + breast cancer-initiating cells to radiation. J. Natl Cancer Inst. 98, 1777-1785 (2006).
27. Debeb, B. G., Xu, W. & Woodward, W. A. Radiation resistance of breast cancer stem cells: understanding the clinical framework. J. Mammary Gland Biol. Neoplasia 14, 11-17 (2009).
28. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
29. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008).
30. Brabletz, T., Lyden, D., Steeg, P. S. & Werb, Z. Roadblocks to translational advances on metastasis research. Nat. Med. 19, 1104-1109 (2013).
31. Camps, C. et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 14, 1340-1348 (2008).
32. Buffa, F. M. et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 71, 5635-5645 (2011).
33. Gutierrez-Puente, Y. et al. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J. Pharmacol. Exp. Ther. 291, 865-869 (1999).
34. Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185-197 (2010).
35. Landen, Jr. C. N. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
36. Nishimura, M. et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 3, 1302-1315 (2013).
37. Yano, J. et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721-7726 (2004).
38. Sung, P. & Klein, H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat. Rev. Mol. Cell Biol. 7, 739-750 (2006).
39. Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633-2638 (1999).
40. Weinstock, D. M., Nakanishi, K., Helgadottir, H. R. & Jasin, M. Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol. 409, 524-540 (2006).
41. Zhang, P. et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat. Cell Biol. 16, 864-875 (2014).
42. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. Cell 115, 787-798 (2003).
43. Krek, A. et al. Combinatorial microRNA target predictions. Nat. Genet. 37, 495-500 (2005).
44. Zhao, G. Y. et al. A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination. Mol. Cell 25, 663-675 (2007).
45. Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls homology-directed DNA repair. Mol. Cell 4, 511-518 (1999).
46. Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G. & Jentsch, S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135-141 (2002).
47. Haracska, L., Torres-Ramos, C. A., Johnson, R. E., Prakash, S. & Prakash, L. Opposing effects of ubiquitin conjugation and SUMO modification of PCNA on replicational bypass of DNA lesions in Saccharomyces cerevisiae. Mol. Cell. Biol. 24, 4267-4274 (2004).
48. Burk, U. et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582-589 (2008).
49. Furusawa, T., Moribe, H., Kondoh, H. & Higashi, Y. Identification of CtBP1 and CtBP2 as corepressors of zinc finger-homeodomain factor deltaEF1. Mol. Cell. Biol. 19, 8581-8590 (1999).
50. Postigo, A. A. & Dean, D. C. ZEB represses transcription through interaction with the corepressor CtBP. Proc. Natl Acad. Sci. USA 96, 6683-6688 (1999).
51. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3, 155-168 (2003).
52. Postigo, A. A., Depp, J. L., Taylor, J. J. & Kroll, K. L. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 22, 2453-2462 (2003).
53. Tucci, P. et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl Acad. Sci. USA 109, 15312-15317 (2012).
54. Lee, J. Y. et al. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 33, 1325-1335 (2014).
55. Karihtala, P. et al. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res. Treat. 138, 81-90 (2013).
56. Graham, T. R. et al. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res. Treat. 123, 139-147 (2010).
57. Wu, H., Zhu, S. & Mo, Y. Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 19, 439-448 (2009).
58. Iorio, M. V. et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69, 2195-2200 (2009).
59. Xu, Y., Brenn, T., Brown, E. R., Doherty, V. & Melton, D. W. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br. J. Cancer 106, 553-561 (2012).
60. Verdoodt, B. et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int. J. Oncol. 43, 307-314 (2013).
61. Kenney, P. A. et al. Novel ZEB1 expression in bladder tumorigenesis. BJU Int. 107, 656-663 (2011).
62. Spoelstra, N. S. et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 66, 3893-3902 (2006).
63. Liu, Y., El-Naggar, S., Darling, D. S., Higashi, Y. & Dean, D. C. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 135, 579-588 (2008).
64. Richardson, C., Moynahan, M. E. & Jasin, M. Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. Genes Dev. 12, 3831-3842 (1998).
65. Wang, L. et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest. New Drugs 30, 2113-2120 (2012).